30.Sep.2008

OCT is initiating a new ophthalmology trial

OCT is glad to announce that the company is starting the trial in neovascular macular degeneration with 3 sites and 15 patients to be enrolled in Baltic States.
OCT is glad to announce that the company is starting the trial in neovascular macular degeneration with 3 sites and 15 patients to be enrolled in Baltic States.